Pharmacodynamics of B-Cell Depletion and Pharmacokinetics of the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Patients With Relapsing Multiple Sclerosis

被引：0

作者：

Fox, E. ^{[1
]}

Steinman, L. ^{[2
]}

Hartung, H. ^{[3
,4
,5
,6
]}

Alvarez, E. ^{[7
]}

Qian, P. ^{[8
]}

Wray, S. ^{[9
]}

Robertson, D. ^{[10
]}

Huang, D. ^{[11
]}

Selmaj, K. ^{[12
]}

Wynn, D. ^{[13
]}

Weiss, M. S. ^{[14
]}

Bosco, J. A. ^{[14
]}

Power, S. A. ^{[14
]}

Mok, K. A. ^{[14
]}

Lee, L. ^{[14
]}

Cree, B. A. ^{[15
]}

机构：

[1] Cent Texas Neurol Consultants, Round Rock, TX USA

[2] Stanford Univ, Stanford, CA 94305 USA

[3] Heinrich Heine Univ, Dusseldorf, Germany

[4] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia

[5] Med Univ Vienna, Vienna, Austria

[6] Palacky Univ, Olomouc, Czech Republic

[7] Univ Colorado, Aurora, CO USA

[8] Swedish Med Ctr, Seattle, WA USA

[9] Hope Neurol, Knoxville, TN USA

[10] Univ S Florida, Tampa, FL 33620 USA

[11] Mt Carmel Hlth Syst, Ctr Multiple Sclerosis, Westerville, OH USA

[12] Univ Warmia & Mazury, Ctr Neurol, Lodz, Poland

[13] Consultants Neurol, Northbrook, IL USA

[14] TG Therapeut Inc, New York, NY USA

[15] Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA 94143 USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 1_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P105

引用

页码：68 / 68

页数：1

共 50 条

[31] Anti-CD20 monoclonal antibodies in multiple sclerosis
Moreno Torres, Irene
Garcia-Merino, Antonio
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2017, 17 (04) : 359 - 371
[32] Anti-CD20 Antibody Therapy for B-Cell Lymphomas
Calcagno, Andrea
Rostagno, Roberto
Di Perri, Giovanni
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (09): : 877 - 878
[33] Anti-CD20 Antibody Therapy for B-Cell Lymphomas
Maloney, David G.
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (21): : 2008 - 2016
[34] B-cell depletion by anti-CD20 antibody treatment in rheumatoid arthritis modulates the B-cell repertoire.
Rouzière, AS
Kneitz, C
Dörner, T
Tony, HP
ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S138 - S138
[35] Study design and patient demographics of the ULTIMATE phase III trials evaluating Ublituximab (UTX), a novel glyco-engineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing multiple sclerosis (RMS)
Steinman, L.
Fox, E.
Hartung, H. -P.
Alvarez, E.
Qian, P.
Wray, S.
Robertson, D.
Huang, D.
Selmaj, K.
Wynn, D.
Weiss, M.
Power, S.
Bosco, J.
Mok, K.
Cree, B.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 523 - 524
[36] The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
Stephen L. Hauser
Ludwig Kappos
Amit Bar-Or
Heinz Wiendl
David Paling
Mitzi Williams
Ralf Gold
Andrew Chan
Ron Milo
Ayan Das Gupta
Goeril Karlsson
Roseanne Sullivan
Gordon Graham
Martin Merschhemke
Dieter A. Häring
Patrick Vermersch
Neurology and Therapy, 2023, 12 : 1491 - 1515
[37] The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
Hauser, Stephen L.
Kappos, Ludwig
Bar-Or, Amit
Wiendl, Heinz
Paling, David
Williams, Mitzi
Gold, Ralf
Chan, Andrew
Milo, Ron
Das Gupta, Ayan
Karlsson, Goeril
Sullivan, Roseanne
Graham, Gordon
Merschhemke, Martin
Haring, Dieter A.
Vermersch, Patrick
NEUROLOGY AND THERAPY, 2023, 12 (05) : 1491 - 1515
[38] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
R Eisenberg
D Albert
J Stansberry
D Tsai
S Kolasinski
S Khan
Arthritis Res Ther, 5
[39] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
Eisenberg, R
Albert, D
Stansberry, J
Tsai, D
Kolasinski, S
Khan, S
ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 3) : S9 - S10
[40] Anti-CD20 monoclonal antibody in multiple sclerosis therapy: the results of phase 3 clinical studies on relapsing and primary progressive multiple sclerosis
Maciejowski, Maciej
AKTUALNOSCI NEUROLOGICZNE, 2015, 15 (03): : 150 - 154

← 1 2 3 4 5 →